Georgia Proposes Home Delivery for Medical Cannabis Patients
Georgia medical cannabis home delivery: Georgia has proposed allowing licensed dispensaries to deliver medical cannabis to registered patients, caregivers, and healthcare institutions. The plan includes identity, registry, quantity, tracking, and…
Illinois Posts New Path for Adult-Use Dispensaries to Serve Medical Cannabis Patients
Illinois medical cannabis dispensary licensing 2026 introduces a new application process for adult-use dispensaries seeking authority to serve medical cannabis patients. Applications begin September 10, 2026, with strict requirements before medical tax…
Utah Opens Its Second Independent Medical Cannabis Pharmacy License Round
Utah medical cannabis pharmacy: Utah has opened the process for its second independent medical cannabis pharmacy license. A strategically placed pharmacy could reduce travel and access burdens for patients. No winner, final location, or opening date has…
Brazil Clarifies Its 2026 Medical Cannabis Rules
Brazil Anvisa medical cannabis rules: Brazil's Anvisa medical cannabis rules now have new implementation guidance. The underlying framework took effect May 4, with an August 1 filing deadline for required product adaptations. The update clarifies…
Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
Policy Watch: 20 Regulatory Updates — June 19, 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone, a synthetic cannabinoid now classified under Schedule I. This reflects regulatory efforts to control emerging psychoactive substances with high abuse potential.…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…